Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 131I-TLX-101 |
Synonyms | |
Therapy Description |
131I-TLX-101 is a derivative of l-phenylalanine radiolabeled with Iodine-131, which is potentially taken up by tumor cells leading to tumor cell cytotoxicity (PMID: 39211520). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
131I-TLX-101 | 131I-IPA|TLX101|TLX 101 | 131I-TLX-101 is a derivative of l-phenylalanine radiolabeled with Iodine-131, which is potentially taken up by tumor cells leading to tumor cell cytotoxicity (PMID: 39211520). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05450744 | Phase I | 131I-TLX-101 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (IPAX-2) | Recruiting | NZL | NLD | AUT | AUS | 0 |